Mycophenolate mofetil and neurological diseases
- 1 March 2005
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 14 (3_suppl) , 42-45
- https://doi.org/10.1191/0961203305lu2117oa
Abstract
We describe experience with the use of mycophenolate mofetil (MMF) in neurological diseases. Although only small series of patients or case reports were described, MMF is promising in immunemediated neuromuscular disorders. MMF has been used for the treatment of polymyositis, chronic inflammatory demyelinating polyradiculoneuropathy, and multifocal motor neuropathy. These studies showed that MMF is well tolerated and may be useful in some patients. MMF can be effective alone but mainly as an adjuvant therapy by reducing steroid requirements or the frequency of infusions of IVIg. MMF has also been tested alone as a single drug treatment or in combination with immunomodulatory drugs in multiple sclerosis in open surveillance trials or in phase II studies. None of these studies have been designed to demonstrate a clinical efficacy but preliminary results are very promising.Keywords
This publication has 18 references indexed in Scilit:
- Mechanisms of action of mycophenolate mofetilLupus, 2005
- Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathyNeurology, 2004
- Mycophenolate mofetil in dysimmune neuropathies: A preliminary studyMuscle & Nerve, 2004
- Mycophenolate Mofetil in Multiple SclerosisClinical Neuropharmacology, 2004
- Inflammatory myopathies: Clinical, diagnostic and therapeutic aspectsMuscle & Nerve, 2003
- Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndromeMuscle & Nerve, 2002
- Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia‐reperfusion injuryNephrology Dialysis Transplantation, 2001
- Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseasesNeurology, 2001
- Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over studyBrain, 1996
- Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatmentAnnals of Neurology, 1982